TherapeuticsMD Inc. (TXMD)

3.69
0.23 5.75
NASDAQ : Health Technology
Prev Close 3.92
Open 3.93
Day Low/High 3.60 / 3.96
52 Wk Low/High 1.82 / 6.09
Volume 3.05M
Avg Volume 3.16M
Exchange NASDAQ
Shares Outstanding 241.22M
Market Cap 948.00M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TherapeuticsMD Announces Participation At The 2019 Cantor Healthcare Conference

TherapeuticsMD Announces Participation At The 2019 Cantor Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference in New York City.

Interesting TXMD Put And Call Options For November 15th

Interesting TXMD Put And Call Options For November 15th

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new November 15th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD Announces Multiple Presentations Related To IMVEXXY® And BIJUVA® At The 2019 Annual Meeting Of The North American Menopause Society

TherapeuticsMD Announces Multiple Presentations Related To IMVEXXY® And BIJUVA® At The 2019 Annual Meeting Of The North American Menopause Society

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the schedule of two oral presentations and five posters that will be presented at the 2019 Annual Meeting of the North American Menopause Society (NAMS) being...

3 Small Biotechs With Favorable Risk Vs. Reward Profiles

3 Small Biotechs With Favorable Risk Vs. Reward Profiles

BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.

First Week Of January 2022 Options Trading For TherapeuticsMD (TXMD)

First Week Of January 2022 Options Trading For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the January 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 857 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Interesting TXMD Put And Call Options For October 18th

Interesting TXMD Put And Call Options For October 18th

Investors in TherapeuticsMD Inc saw new options become available this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new October 18th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD Announces Second Quarter 2019 Financial Results

TherapeuticsMD Announces Second Quarter 2019 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the second quarter ended June 30, 2019 and provided a business update.

TherapeuticsMD To Report Second Quarter 2019 Results On August 6, 2019

TherapeuticsMD To Report Second Quarter 2019 Results On August 6, 2019

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019, after the closing of the U.

First Week Of March 2020 Options Trading For TherapeuticsMD (TXMD)

First Week Of March 2020 Options Trading For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the March 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Rally Runs Low on Fuel: Cramer's 'Mad Money' Recap (Tuesday 6/11/19)

Rally Runs Low on Fuel: Cramer's 'Mad Money' Recap (Tuesday 6/11/19)

Cramer says rallies need fuel, and without it, we end up with what we got Tuesday: a soggy session that reminds us stocks can go down, too.

Yeti Holdings, Canopy Growth, Dermira: 'Mad Money' Lightning Round

Yeti Holdings, Canopy Growth, Dermira: 'Mad Money' Lightning Round

Jim Cramer takes a look at Yeti Holdings, Canopy Growth, Dermira, Daktronics, TherapeuticsMD, Rite Aid, Genpact and California Water Services.

TherapeuticsMD To Host Investor And Analyst Day Today

TherapeuticsMD To Host Investor And Analyst Day Today

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, will host its Investor and Analyst Day today in New York City.

TherapeuticsMD And Theramex Enter Into Exclusive License And Supply Agreement To Commercialize BIJUVA™ And IMVEXXY® Outside The United States

TherapeuticsMD And Theramex Enter Into Exclusive License And Supply Agreement To Commercialize BIJUVA™ And IMVEXXY® Outside The United States

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it has entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to...

TherapeuticsMD To Host Investor And Analyst Day On June 10, 2019 In New York City

TherapeuticsMD To Host Investor And Analyst Day On June 10, 2019 In New York City

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will host an Investor and Analyst Day on Monday, June 10, 2019, in New York City.

Interesting TXMD Put And Call Options For July 19th

Interesting TXMD Put And Call Options For July 19th

Investors in TherapeuticsMD Inc saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD Announces Participation At The Bank Of America Merrill Lynch 2019 Health Care Conference

TherapeuticsMD Announces Participation At The Bank Of America Merrill Lynch 2019 Health Care Conference

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that the company will participate in the Bank of America Merrill Lynch 2019 Health Care Conference.

TherapeuticsMD Announces First Quarter 2019 Financial Results

TherapeuticsMD Announces First Quarter 2019 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced its commercial and corporate update for the first quarter ended March 31, 2019.

TherapeuticsMD Presented New Research At The American College Of Obstetricians And Gynecologists 2019 Annual Meeting That Explores How Women's Menopausal Symptoms Affect Men

TherapeuticsMD Presented New Research At The American College Of Obstetricians And Gynecologists 2019 Annual Meeting That Explores How Women's Menopausal Symptoms Affect Men

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the presentation of results from the Men's Attitude Toward Menopause Survey (MATE), a large study of men's understanding of and attitudes related to...

TherapeuticsMD Announces Oral And Poster Presentations On BIJUVA™ And ANNOVERA™ At The American College Of Obstetricians And Gynecologists 2019 Annual Meeting

TherapeuticsMD Announces Oral And Poster Presentations On BIJUVA™ And ANNOVERA™ At The American College Of Obstetricians And Gynecologists 2019 Annual Meeting

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the schedule of presentations on BIJUVA TM (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERA™ (segesterone acetate/ethinyl estradiol...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TherapeuticsMD, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TherapeuticsMD, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

NEW YORK, May 2, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of TherapeuticsMD,...

Interesting TXMD Put And Call Options For December 20th

Interesting TXMD Put And Call Options For December 20th

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the December 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TherapeuticsMD To Report First Quarter 2019 Results On May 6, 2019

TherapeuticsMD To Report First Quarter 2019 Results On May 6, 2019

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will report its first quarter 2019 financial results on Monday, May 6, 2019, after the closing of the U.

TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility With TPG Sixth Street Partners

TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility With TPG Sixth Street Partners

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it has closed its previously disclosed $300 million non-dilutive secured term loan financing facility with TPG Sixth Street Partners ("TSSP"), the...

TherapeuticsMD Signs Binding Commitment Letter For $300 Million Non-Dilutive Term Loan Financing Facility With TPG Sixth Street Partners

TherapeuticsMD Signs Binding Commitment Letter For $300 Million Non-Dilutive Term Loan Financing Facility With TPG Sixth Street Partners

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it has signed a binding commitment letter for a fully-negotiated $300 million non-dilutive secured term loan financing facility with TPG Sixth...

TherapeuticsMD Announces Commercial Availability Of BIJUVA™ In The U.S.

TherapeuticsMD Announces Commercial Availability Of BIJUVA™ In The U.S.

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the commercial availability of BIJUVA TM (estradiol and progesterone capsules, 1 mg/100 mg) in the United States.

TherapeuticsMD Announces Oral And Poster Presentations On BIJUVA™ And ANNOVERA™ At The Endocrine Society 2019 Annual Meeting

TherapeuticsMD Announces Oral And Poster Presentations On BIJUVA™ And ANNOVERA™ At The Endocrine Society 2019 Annual Meeting

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the schedule of presentations on BIJUVA™ (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERA™ (segesterone acetate/ethinyl estradiol...

TherapeuticsMD Announces Oral Presentations On BIJUVA And ANNOVERA, And Poster Presentations Related To Menopause Symptoms And Treatments At 2019 ISSWSH/ISSM Joint Meeting

TherapeuticsMD Announces Oral Presentations On BIJUVA And ANNOVERA, And Poster Presentations Related To Menopause Symptoms And Treatments At 2019 ISSWSH/ISSM Joint Meeting

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the schedule of oral presentations on clinical data for BIJUVA TM (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERA TM (segesterone...

TherapeuticsMD Announces Participation In Two Upcoming Investor Conferences

TherapeuticsMD Announces Participation In Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that the company will participate in two upcoming healthcare conferences.

TheStreet Quant Rating: D- (Sell)